Establishment of OPG transgenic mice and the effect of OPG on bone microarchitecture

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Wu, Ying ^a   Liu, Jianghua ^a   Guo, Hui ^a   Luo, Qiong ^a   Yu, Ziying ^a   Liao, Eryuan ^b   Zu, Xuyu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE STRUCTURE; C57BL 6 MOUSE; CBA MOUSE; CONTROLLED STUDY; CORTICAL BONE; FEMALE; FEMUR; GENE CONSTRUCT; GENE CONTROL; GENE VECTOR; MALE; MICRO-COMPUTED TOMOGRAPHY; MICROINJECTION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TIBIA; TRABECULAR BONE; TRANSGENIC MOUSE; WESTERN BLOTTING; WILD TYPE; ZYGOTE;

EID: 84876516915     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/125932     Document Type: Article

References (24)

1. Lacey D. L., Boyle W. J., Simonet W. S., Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nature Reviews Drug Discovery 2012 11 5 401 419
2. Honsawek S., Chaiwatanarat T., Vejchapipat P., Chongsrisawat V., Thawornsuk N., Poovorawan Y., Relationships between OPG, RANKL, bone metabolism, and bone mineral density in biliary atresia. Pediatric Surgery International 2009 25 3 261 267 2-s2.0-61449120925 10.1007/s00383-009-2325-y
3. Baek K. H., Oh K. W., Lee W. Y., Tae H. J., Rhee E. J., Han J. H., Cha B. Y., Kim Y. J., Lee K. W., Son H. Y., Kang S. K., Kim C. C., Kang M. I., Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism. Bone 2006 39 6 1352 1360 2-s2.0-35348832763 10.1016/j.bone.2006.06.011 (Pubitemid 44827917)
4. Jurado S., Garcia-Giralt N., Diez-Perez A., Esbrit P., Yoskovitz G., Agueda L., Urreizti R., Pérez-Edo L., Saló G., Mellibovsky L., Balcells S., Grinberg D., Nogués X., Effect of IL-1 β PGE2, and TGF- β 1 on the expression of OPG and RANKL in normal and osteoporotic primary human osteoblasts. Journal of Cellular Biochemistry 2010 110 2 304 310 2-s2.0-77952070589 10.1002/jcb.22538
5. Kwan Tat S., Pelletier J. P., Lajeunesse D., Fahmi H., Lavigne M., Martel-Pelletier J., The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor B ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells. Clinical and Experimental Rheumatology 2008 26 2 295 304 2-s2.0-43349095508 (Pubitemid 351659137)
6. Tat S. K., Pelletier J. P., Lajeunesse D., Fahmi H., Duval N., Martel-Pelletier J., Differential modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: influence of osteotropic factors. Bone 2008 43 2 284 291 2-s2.0-52449116752 10.1016/j.bone.2008.04.006
7. Wang Y., Huang P., Tang P. F., Chan K. M., Li G., Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. Journal of Orthopaedic Surgery and Research 2011 6 1, article 34 2-s2.0-79960129388 10.1186/1749-799X-6-34
8. Zupan J., Mencej-Bedrač S., Jurković-Mlakar S., Preželj J., Marc J., Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology 2010 118 1-2 102 106 2-s2.0-72449128490 10.1016/j.jsbmb.2009.10.013
9. Malliga D. E., Wagner D., Fahrleitner-Pammer A., The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappaB ligand (RANKL) in cardiovascular pathology-a review. Wiener Medizinische Wochenschrift 2011 161 23-24 565 570
10. Montecucco F., Steffens S., Mach F., The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clinical & Developmental Immunology 2007 2007 75805 2-s2.0-41449113349
11. Miao X., Recent advances in the development of new transgenic animal technology. Cellular and Molecular Life Sciences 2012 70 5 815 828 10.1007/s00018-012-1081-7
12. Liu J., Xu K., Wen G., Guo H., Li S., Wu X., Dai R., Sheng Z., Liao E., Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice. Bone 2008 42 5 950 959 2-s2.0-41949105172 10.1016/j.bone.2008.01.010
13. Cui R. R., Li S. J., Liu L. J., MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo. Cardiovascular Research 2012 96 320 329
14. Liang Q. H., Jiang Y., Zhu X., Ghrelin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the ERK pathway. PLoS ONE 2012 7 4 33126
15. Trouvin A. P., Goëb V., Receptor activator of nuclear factor- B ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clinical Interventions in Aging 2010 5 345 354 2-s2.0-79952641200
16. Montagnana M., Lippi G., Danese E., Guidi G. C., The role of osteoprotegerin in cardiovascular disease. Annals of Internal Medicine 2012 10.3109/07853890.2012.727019
17. Hou L. L. E., Hou J. F. A., Yao J., Zhou Z. L., Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts. Acta Veterinaria Scandinavica 2011 53, article 21 2-s2.0-79953072982 10.1186/1751-0147-53-21
18. Bucay N., Sarosi I., Dunstan C. R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H. L., Xu W., Lacey D. L., Boyle W. J., Simonet W. S., Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998 12 9 1260 1268 2-s2.0-0032079445 (Pubitemid 28213402)
19. Omland T., Ueland T., Jansson A. M., Persson A., Karlsson T., Smith C., Herlitz J., Aukrust P., Hartford M., Caidahl K., Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. Journal of the American College of Cardiology 2008 51 6 627 633 2-s2.0-38849186660 10.1016/j.jacc.2007.09.058 (Pubitemid 351193104)
20. Mueller C. G., Hess E., Emerging functions of RANKL in lymphoid tissues. Frontiers in Immunology 2012 3 261
21. Tabuchi M., Miyazawa K., Kimura M., Maeda H., Kawai T., Kameyama Y., Goto S., Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice. Calcified Tissue International 2005 77 4 239 249 2-s2.0-27444445520 10.1007/s00223-004-0223-9 (Pubitemid 41531504)
22. Sasaki F., Okuno T., Saeki K., A high-affinity monoclonal antibody against the FLAG tag useful for G-protein-coupled receptor study. Analytical Biochemistry 2012 425 2 157 165
23. Vasquez S. X., Shah N., Hoberman A. M., Small animal imaging and examination by micro-CT. Methods in Molecular Biology 2013 947 223 231
24. Ominsky M. S., Stolina M., Li X., Corbin T. J., Asuncion F. J., Barrero M., Niu Q. T., Dwyer D., Adamu S., Warmington K. S., Grisanti M., Tan H. L., Ke H. Z., Simonet W. S., Kostenuik P. J., One year of transgenic overexpression of osteoprotegerin in rats suppressed bone resorption and increased vertebral bone volume, density, and strength. Journal of Bone and Mineral Research 2009 24 7 1234 1246 2-s2.0-70349100858 10.1359/jbmr.090215